Navigation Links
Edison highlights the potential of GW Pharmaceuticals' cannabinoid pipeline and furthers its US healthcare presence
Date:12/10/2013

an>Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website www.edisongroup.com.

Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information please contact:Lala GregorekEdison Investment Research+44 (0)20 3681 2527Robin DavisonEdison Investment Research+44 (0)20 3077 5737healthcare@edisongroup.comAbout GW Pharmaceuticals  GW Pharmaceuticals is a UK specialty pharma company focused on developing cannabinoids as pharmaceuticals. Lead product Sativex is marketed in a number of European countries for multiple sclerosis-associated spasticity.


'/>"/>
SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
2. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Edison Pharmaceuticals Closes $20M Series F Financing
8. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
9. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
10. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
11. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015   KaloBios Pharmaceuticals, Inc . (Nasdaq: ... innovative therapies to benefit patients with diseases of unmet ... that the U.S. Food and Drug Administration (FDA) has ... KB003, an anti-GM-CSF monoclonal antibody (mAb), in patients with ... now active. The acceptance of this IND ...
(Date:7/29/2015)... 27, 2015 Research and Markets ( http://www.researchandmarkets.com/research/sxwk89/3d_metrology ... Metrology Market by Product (CMM, ODS, and VMM), Application ... Geography (North America, Europe, APAC, RoW) - Global Forecast ... The 3D metrology market was valued at ... at a rate of 7.11% during the forecast period. ...
(Date:7/29/2015)... The Judicial Panel on Multidistrict Litigation (JPML) ... centralize Inferior vena cava (IVC) Filter lawsuits filed against ... have already been centralized by the JPML. ... risk for a pulmonary embolism. The filters are designed ... Claims against Bard and Cook involve incidents of retrievable ...
Breaking Medicine Technology:KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5Global 3D Metrology Market 2015-2020: Products (CMM, ODS, and VMM) & Applications (Automotive, Aerospace, Energy & Power, Medical and Electronics) 2IVC filter litigation continues; law firm provides free information to IVC filter patients 2
... , , , ... AMGN ) today announced positive top-line results from a pivotal ... acid) administered as an intravenous (IV) infusion in the treatment of ... including breast and prostate cancer) or multiple myeloma. , ...
... , , , , ... Institute (KLRI) has published two new publications on hormone therapies and ... adults. , , Cardiovascular disease caused by atherosclerosis, ... greatest single killer of American women--40% of total deaths--and the rate ...
Cached Medicine Technology:Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 2Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 3Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 4Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 5Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 6Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 7Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) 8TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 2TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men 3
(Date:7/29/2015)... ... July 29, 2015 , ... ... with its Topricin® Pain Relief and Healing Cream designated as the nonprofit’s natural ... that is actively addressing Line of Duty Deaths (LODD) and the high rate ...
(Date:7/29/2015)... Miami, FL (PRWEB) , ... July 29, 2015 , ... ... on fruit flies revealed a gene which is directly responsible for stimulating and perpetuating ... was published in the journal entitled Proceedings of the National academy of Sciences, and ...
(Date:7/29/2015)... ... 29, 2015 , ... On July 26th the Miami ... for nicotine laced liquid products. Their report says cigarette use has decreased recently ... particularly troublesome to addiction professionals as many of the candy flavors available are ...
(Date:7/29/2015)... MI (PRWEB) , ... July 29, 2015 , ... ... for Southwest Michigan, changed its name in July to Kalamazoo Strength & Conditioning. ... http://www.kalamazoosc.com , and “reflects the evolution of our training center over the ...
(Date:7/29/2015)... , ... July 29, 2015 , ... San Fernando ... on Ultherapy. For a limited time only, patients can get the complete treatment process ... for patients who prefer a non-invasive treatment and have loose or sagging skin. ...
Breaking Medicine News(10 mins):Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2
... San Diego, Calif., USA Today, during the 89th ... Dental Research, held in conjunction with the 40th Annual ... the 35th Annual Meeting of the Canadian Association for ... oral presentation on a research study titled "Sealing Manifest ...
... Reporter , THURSDAY, March 17 (HealthDay News) -- Cutting-edge ... tremors, rigidity and other motor skill problems that are ... The phase 2 study enrolled 45 patients with ... to receive the gene therapy and half assigned to ...
... March 17, 2011 (BRONX, NY) The National Institutes ... Albert Einstein College of Medicine and Ferkauf Graduate ... identify cognitive factors that influence mobility in older people ... people remain active. , "Mobility limitations and disability in aging ...
... 2011) Many Baby Boomers will experience a bone fracture as ... prepared to provide the necessary care required, according to a ... Geriatric Orthopaedic Surgery and Rehabilitation (GOS), published by SAGE. ... II Baby Boom generation will reach 65 years old this ...
... at the University of Cincinnati (UC) and Cincinnati ... FDA-approved drug sirolimus, used primarily to prevent rejection ... women with lymphangioleiomyomatosis (LAM). The Multicenter International ... first randomized, controlled study designed to develop a ...
... HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... reached an all-time low in 2009, the 10th straight ... health officials report. , "There is basically good news," ... U.S. Centers for Disease Control and Prevention,s National Center ...
Cached Medicine News:Health News:Sealing manifest occlusal caries in permanent teeth -- 2.5-year results 2Health News:Gene Therapy May Help Reverse Parkinson's Symptoms 2Health News:Gene Therapy May Help Reverse Parkinson's Symptoms 3Health News:$3.4 million grant awarded to help older people stay mobile 2Health News:US healthcare system can't keep up with number of baby boomers' bone fractures 2Health News:New therapy found for rare lung disorder 2Health News:New therapy found for rare lung disorder 3Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3
... Examination Tables deliver the highest quality care to ... types of patients can face a frustrating dilemma ... the exam table. Being able to easily get ... comfort during the exam, help the physician conduct ...
... This site introduces the DiamondTome™ ... with its unique DiamondTome™ Wands, an ... better way to smoother, more youthful ... we present the benefits of DiamondTome's™ ...
... Expand your practice with the advantages of ... effective treatment of leg veins and other deeper ... and fast. As a stand alone device or ... the Quantum DL treats a range of conditions ...
Inquire...
Medicine Products: